Skip to main content
Erschienen in: Zeitschrift für Epileptologie 4/2018

30.08.2018 | Epilepsie | Leitthema

Topiramat, Perampanel und Brivaracetam im Status epilepticus

Wie anzuwenden und was können wir erwarten?

verfasst von: Alexandra Rohracher, PD Dr. Christoph Kellinghaus, Adam Strzelczyk

Erschienen in: Clinical Epileptology | Ausgabe 4/2018

Einloggen, um Zugang zu erhalten

Zusammenfassung

Im Status epilepticus werden bei Versagen der Erstlinientherapie mit Benzodiazepinen und intravenösen Antikonvulsiva wie Phenytoin, Valproat oder Levetiracetam weitere Substanzen eingesetzt. In diesem Beitrag werden die zum aktuellen Zeitpunkt vorliegenden Daten und publizierten Erfahrungen zum Einsatz von 2 ausschließlich enteral (Topiramat, Perampanel) und einem enteral und parenteral verfügbaren Antikonvulsivum (Brivaracetam) zusammengefasst, die pharmakologisch und klinisch relevanten Daten im Einsatz dieser Substanzen im SE dargestellt und Empfehlungen zum praktischen klinischen Einsatz gegeben.
Literatur
1.
Zurück zum Zitat Sutter R, De Marchis GM, Semmlack S, Fuhr P, Ruegg S, Marsch S et al (2017) Anesthetics and outcome in status epilepticus: a matched two-center cohort study. CNS Drugs 31(1):65–74CrossRef Sutter R, De Marchis GM, Semmlack S, Fuhr P, Ruegg S, Marsch S et al (2017) Anesthetics and outcome in status epilepticus: a matched two-center cohort study. CNS Drugs 31(1):65–74CrossRef
2.
Zurück zum Zitat Sutter R, Marsch S, Fuhr P, Kaplan PW, Ruegg S (2014) Anesthetic drugs in status epilepticus: risk or rescue? A 6‑year cohort study. Neurology 82(8):656–664CrossRef Sutter R, Marsch S, Fuhr P, Kaplan PW, Ruegg S (2014) Anesthetic drugs in status epilepticus: risk or rescue? A 6‑year cohort study. Neurology 82(8):656–664CrossRef
3.
Zurück zum Zitat Alvarez V, Lee JW, Westover MB, Drislane FW, Novy J, Faouzi M et al (2016) Therapeutic coma for status epilepticus: differing practices in a prospective multicenter study. Neurology 87(16):1650–1659CrossRef Alvarez V, Lee JW, Westover MB, Drislane FW, Novy J, Faouzi M et al (2016) Therapeutic coma for status epilepticus: differing practices in a prospective multicenter study. Neurology 87(16):1650–1659CrossRef
4.
Zurück zum Zitat Beuchat I, Novy J, Rossetti AO (2018) Newer antiepileptic drugs for status epilepticus in adults: What’s the evidence? CNS Drugs 32(3):259–267CrossRef Beuchat I, Novy J, Rossetti AO (2018) Newer antiepileptic drugs for status epilepticus in adults: What’s the evidence? CNS Drugs 32(3):259–267CrossRef
5.
Zurück zum Zitat Shorvon S, Ferlisi M (2011) The treatment of super-refractory status epilepticus: a critical review of available therapies and a clinical treatment protocol. Brain 134(Pt 10):2802–2818CrossRef Shorvon S, Ferlisi M (2011) The treatment of super-refractory status epilepticus: a critical review of available therapies and a clinical treatment protocol. Brain 134(Pt 10):2802–2818CrossRef
6.
Zurück zum Zitat Strzelczyk A, Ansorge S, Hapfelmeier J, Bonthapally V, Erder MH, Rosenow F (2017) Costs, length of stay, and mortality of super-refractory status epilepticus: a population-based study from Germany. Epilepsia 58(9):1533–1541CrossRef Strzelczyk A, Ansorge S, Hapfelmeier J, Bonthapally V, Erder MH, Rosenow F (2017) Costs, length of stay, and mortality of super-refractory status epilepticus: a population-based study from Germany. Epilepsia 58(9):1533–1541CrossRef
7.
Zurück zum Zitat Rosenfeld WE (1997) Topiramate: a review of preclinical, pharmacokinetic, and clinical data. Clin Ther 19(6):1294–1308CrossRef Rosenfeld WE (1997) Topiramate: a review of preclinical, pharmacokinetic, and clinical data. Clin Ther 19(6):1294–1308CrossRef
8.
Zurück zum Zitat Clark AM, Kriel RL, Leppik IE, Marino SE, Mishra U, Brundage RC et al (2013) Intravenous topiramate: comparison of pharmacokinetics and safety with the oral formulation in healthy volunteers. Epilepsia 54(6):1099–1105CrossRef Clark AM, Kriel RL, Leppik IE, Marino SE, Mishra U, Brundage RC et al (2013) Intravenous topiramate: comparison of pharmacokinetics and safety with the oral formulation in healthy volunteers. Epilepsia 54(6):1099–1105CrossRef
9.
Zurück zum Zitat Clark AM, Kriel RL, Leppik IE, White JR, Henry TR, Brundage RC et al (2013) Intravenous topiramate: safety and pharmacokinetics following a single dose in patients with epilepsy or migraines taking oral topiramate. Epilepsia 54(6):1106–1111CrossRef Clark AM, Kriel RL, Leppik IE, White JR, Henry TR, Brundage RC et al (2013) Intravenous topiramate: safety and pharmacokinetics following a single dose in patients with epilepsy or migraines taking oral topiramate. Epilepsia 54(6):1106–1111CrossRef
10.
Zurück zum Zitat Reuber M, Evans J, Bamford JM (2002) Topiramate in drug-resistant complex partial status epilepticus. Eur J Neurol 9(1):111–112CrossRef Reuber M, Evans J, Bamford JM (2002) Topiramate in drug-resistant complex partial status epilepticus. Eur J Neurol 9(1):111–112CrossRef
11.
Zurück zum Zitat Towne AR, Garnett LK, Waterhouse EJ, Morton LD, DeLorenzo RJ (2003) The use of topiramate in refractory status epilepticus. Neurology 60(2):332–334CrossRef Towne AR, Garnett LK, Waterhouse EJ, Morton LD, DeLorenzo RJ (2003) The use of topiramate in refractory status epilepticus. Neurology 60(2):332–334CrossRef
12.
Zurück zum Zitat Kortland LM, Alfter A, Bahr O, Carl B, Dodel R, Freiman TM et al (2016) Costs and cost-driving factors for acute treatment of adults with status epilepticus: a multicenter cohort study from Germany. Epilepsia 57(12):2056–2066CrossRef Kortland LM, Alfter A, Bahr O, Carl B, Dodel R, Freiman TM et al (2016) Costs and cost-driving factors for acute treatment of adults with status epilepticus: a multicenter cohort study from Germany. Epilepsia 57(12):2056–2066CrossRef
13.
Zurück zum Zitat Kellinghaus C, Rossetti AO, Trinka E, Lang N, Unterberger I, Ruegg S et al (2018) SENSE registry for status epilepticus. Epilepsia 59: in pressCrossRef Kellinghaus C, Rossetti AO, Trinka E, Lang N, Unterberger I, Ruegg S et al (2018) SENSE registry for status epilepticus. Epilepsia 59: in pressCrossRef
14.
Zurück zum Zitat Perry MS, Holt PJ, Sladky JT (2006) Topiramate loading for refractory status epilepticus in children. Epilepsia 47(6):1070–1071CrossRef Perry MS, Holt PJ, Sladky JT (2006) Topiramate loading for refractory status epilepticus in children. Epilepsia 47(6):1070–1071CrossRef
15.
Zurück zum Zitat Brigo F, Trinka E (2017) Randomized controlled trials in status epilepticus: size matters. Epilepsia 58(5):915CrossRef Brigo F, Trinka E (2017) Randomized controlled trials in status epilepticus: size matters. Epilepsia 58(5):915CrossRef
16.
Zurück zum Zitat Brigo F, Bragazzi NL, Igwe SC, Nardone R, Trinka E (2017) Topiramate in the treatment of generalized convulsive status epilepticus in adults: a systematic review with individual patient data analysis. Drugs 77(1):67–74CrossRef Brigo F, Bragazzi NL, Igwe SC, Nardone R, Trinka E (2017) Topiramate in the treatment of generalized convulsive status epilepticus in adults: a systematic review with individual patient data analysis. Drugs 77(1):67–74CrossRef
17.
Zurück zum Zitat Synowiec AS, Yandora KA, Yenugadhati V, Valeriano JP, Schramke CJ, Kelly KM (2012) The efficacy of topiramate in adult refractory status epilepticus: experience of a tertiary care center. Epilepsy Res 98(2–3):232–237CrossRef Synowiec AS, Yandora KA, Yenugadhati V, Valeriano JP, Schramke CJ, Kelly KM (2012) The efficacy of topiramate in adult refractory status epilepticus: experience of a tertiary care center. Epilepsy Res 98(2–3):232–237CrossRef
18.
Zurück zum Zitat Strzelczyk A, Willems LM, Willig S, Rosenow F, Bauer S (2015) Perampanel in the treatment of focal and idiopathic generalized epilepsies and of status epilepticus. Expert Rev Clin Pharmacol 8(6):733–740CrossRef Strzelczyk A, Willems LM, Willig S, Rosenow F, Bauer S (2015) Perampanel in the treatment of focal and idiopathic generalized epilepsies and of status epilepticus. Expert Rev Clin Pharmacol 8(6):733–740CrossRef
19.
Zurück zum Zitat Niquet J, Baldwin R, Suchomelova L, Lumley L, Naylor D, Eavey R et al (2016) Benzodiazepine-refractory status epilepticus: pathophysiology and principles of treatment. Ann N Y Acad Sci 1378(1):166–173CrossRef Niquet J, Baldwin R, Suchomelova L, Lumley L, Naylor D, Eavey R et al (2016) Benzodiazepine-refractory status epilepticus: pathophysiology and principles of treatment. Ann N Y Acad Sci 1378(1):166–173CrossRef
20.
Zurück zum Zitat Naylor DE, Liu H, Wasterlain CG (2005) Trafficking of GABA(A) receptors, loss of inhibition, and a mechanism for pharmacoresistance in status epilepticus. J Neurosci 25(34):7724–7733CrossRef Naylor DE, Liu H, Wasterlain CG (2005) Trafficking of GABA(A) receptors, loss of inhibition, and a mechanism for pharmacoresistance in status epilepticus. J Neurosci 25(34):7724–7733CrossRef
21.
Zurück zum Zitat Wasterlain CG, Liu H, Naylor DE, Thompson KW, Suchomelova L, Niquet J et al (2009) Molecular basis of self-sustaining seizures and pharmacoresistance during status epilepticus: the receptor trafficking hypothesis revisited. Epilepsia 50(Suppl 12):16–18CrossRef Wasterlain CG, Liu H, Naylor DE, Thompson KW, Suchomelova L, Niquet J et al (2009) Molecular basis of self-sustaining seizures and pharmacoresistance during status epilepticus: the receptor trafficking hypothesis revisited. Epilepsia 50(Suppl 12):16–18CrossRef
22.
Zurück zum Zitat Di Bonaventura C, Labate A, Maschio M, Meletti S, Russo E (2017) AMPA receptors and perampanel behind selected epilepsies: current evidence and future perspectives. Expert Opin Pharmacother 18(16):1751–1764CrossRef Di Bonaventura C, Labate A, Maschio M, Meletti S, Russo E (2017) AMPA receptors and perampanel behind selected epilepsies: current evidence and future perspectives. Expert Opin Pharmacother 18(16):1751–1764CrossRef
23.
Zurück zum Zitat Patsalos PN (2015) The clinical pharmacology profile of the new antiepileptic drug perampanel: a novel noncompetitive AMPA receptor antagonist. Epilepsia 56(1):12–27CrossRef Patsalos PN (2015) The clinical pharmacology profile of the new antiepileptic drug perampanel: a novel noncompetitive AMPA receptor antagonist. Epilepsia 56(1):12–27CrossRef
24.
Zurück zum Zitat French JA, Krauss GL, Biton V, Squillacote D, Yang H, Laurenza A et al (2012) Adjunctive perampanel for refractory partial-onset seizures: randomized phase III study 304. Neurology 79(6):589–596CrossRef French JA, Krauss GL, Biton V, Squillacote D, Yang H, Laurenza A et al (2012) Adjunctive perampanel for refractory partial-onset seizures: randomized phase III study 304. Neurology 79(6):589–596CrossRef
25.
Zurück zum Zitat French JA, Krauss GL, Steinhoff BJ, Squillacote D, Yang H, Kumar D et al (2013) Evaluation of adjunctive perampanel in patients with refractory partial-onset seizures: results of randomized global phase III study 305. Epilepsia 54(1):117–125CrossRef French JA, Krauss GL, Steinhoff BJ, Squillacote D, Yang H, Kumar D et al (2013) Evaluation of adjunctive perampanel in patients with refractory partial-onset seizures: results of randomized global phase III study 305. Epilepsia 54(1):117–125CrossRef
26.
Zurück zum Zitat Krauss GL, Serratosa JM, Villanueva V, Endziniene M, Hong Z, French J et al (2012) Randomized phase III study 306: adjunctive perampanel for refractory partial-onset seizures. Neurology 78(18):1408–1415CrossRef Krauss GL, Serratosa JM, Villanueva V, Endziniene M, Hong Z, French J et al (2012) Randomized phase III study 306: adjunctive perampanel for refractory partial-onset seizures. Neurology 78(18):1408–1415CrossRef
27.
Zurück zum Zitat Krauss GL, Perucca E, Ben-Menachem E, Kwan P, Shih JJ, Clement JF et al (2014) Long-term safety of perampanel and seizure outcomes in refractory partial-onset seizures and secondarily generalized seizures: results from phase III extension study 307. Epilepsia 55(7):1058–1068CrossRef Krauss GL, Perucca E, Ben-Menachem E, Kwan P, Shih JJ, Clement JF et al (2014) Long-term safety of perampanel and seizure outcomes in refractory partial-onset seizures and secondarily generalized seizures: results from phase III extension study 307. Epilepsia 55(7):1058–1068CrossRef
28.
Zurück zum Zitat Hanada T, Ido K, Kosasa T (2014) Effect of perampanel, a novel AMPA antagonist, on benzodiazepine-resistant status epilepticus in a lithium-pilocarpine rat model. Pharmacol Res Perspect 2(5):e63CrossRef Hanada T, Ido K, Kosasa T (2014) Effect of perampanel, a novel AMPA antagonist, on benzodiazepine-resistant status epilepticus in a lithium-pilocarpine rat model. Pharmacol Res Perspect 2(5):e63CrossRef
30.
Zurück zum Zitat Santamarina E, Sueiras M, Lidon RM, Guzman L, Baneras J, Gonzalez M et al (2015) Use of perampanel in one case of super-refractory hypoxic myoclonic status: case report. Epilepsy Behav Case Rep 4:56–59CrossRef Santamarina E, Sueiras M, Lidon RM, Guzman L, Baneras J, Gonzalez M et al (2015) Use of perampanel in one case of super-refractory hypoxic myoclonic status: case report. Epilepsy Behav Case Rep 4:56–59CrossRef
31.
Zurück zum Zitat Redecker J, Wittstock M, Benecke R, Rosche J (2015) Efficacy of perampanel in refractory nonconvulsive status epilepticus and simple partial status epilepticus. Epilepsy Behav 45:176–179CrossRef Redecker J, Wittstock M, Benecke R, Rosche J (2015) Efficacy of perampanel in refractory nonconvulsive status epilepticus and simple partial status epilepticus. Epilepsy Behav 45:176–179CrossRef
32.
Zurück zum Zitat Rohracher A, Hofler J, Kalss G, Leitinger M, Kuchukhidze G, Deak I et al (2015) Perampanel in patients with refractory and super-refractory status epilepticus in a neurological intensive care unit. Epilepsy Behav 49:354–358CrossRef Rohracher A, Hofler J, Kalss G, Leitinger M, Kuchukhidze G, Deak I et al (2015) Perampanel in patients with refractory and super-refractory status epilepticus in a neurological intensive care unit. Epilepsy Behav 49:354–358CrossRef
33.
Zurück zum Zitat Mirandola L, Giovannini G, Monti G, Meletti S (2017) High-dose perampanel in super refractory status epilepticus: effects on EEG and vital parameters. 32nd International Epilepsy Congress 2017. Abstract A‑905-0017-01108 Mirandola L, Giovannini G, Monti G, Meletti S (2017) High-dose perampanel in super refractory status epilepticus: effects on EEG and vital parameters. 32nd International Epilepsy Congress 2017. Abstract A‑905-0017-01108
34.
Zurück zum Zitat Alsherbini KM, Jones G, Goyal N (2017) The use and efficary of Perampanel in refractory status epilepticus. AES Annual Meeting 2017. (Abst. 1.194) Alsherbini KM, Jones G, Goyal N (2017) The use and efficary of Perampanel in refractory status epilepticus. AES Annual Meeting 2017. (Abst. 1.194)
35.
Zurück zum Zitat Beretta S, Padovano G, Stabile A, Coppo A, Bogliun G, Avalli L, Ferrarese C (2017) Efficacy and safety of perampanel oral loading in post-anoxic super-refractory status epilepticus: a case series. Epilepsia 58(Suppl. 5):S5–S199 (p0444) Beretta S, Padovano G, Stabile A, Coppo A, Bogliun G, Avalli L, Ferrarese C (2017) Efficacy and safety of perampanel oral loading in post-anoxic super-refractory status epilepticus: a case series. Epilepsia 58(Suppl. 5):S5–S199 (p0444)
36.
Zurück zum Zitat Kjaer TW, Atkins M, Friedrich J, Gyllenborg J (2017) The efficacy of perampanel in refractory status epilepticus. Epilepsia 58(Suppl. 5):S5–S199 (p0550) Kjaer TW, Atkins M, Friedrich J, Gyllenborg J (2017) The efficacy of perampanel in refractory status epilepticus. Epilepsia 58(Suppl. 5):S5–S199 (p0550)
37.
Zurück zum Zitat Rohracher A, Höfler J, Kalss G, Leitinger M, Kuchukhidze G, Neuray C, Dobesberger J, Trinka E (2016) Perampanel in patients with refractory and super-refractory status epilepticus in a neurological intensive care unit. AES Annual Meeting. (Abst. 1.289) Rohracher A, Höfler J, Kalss G, Leitinger M, Kuchukhidze G, Neuray C, Dobesberger J, Trinka E (2016) Perampanel in patients with refractory and super-refractory status epilepticus in a neurological intensive care unit. AES Annual Meeting. (Abst. 1.289)
38.
Zurück zum Zitat Sueiras MS, Santamarina E, Lidon RM, Guzman L, Baneras J, Gonzalez M, Toledo M, Salas-Puig X (2015) Use of perampanel (per) in two cases of super-refractory hypoxic myoclonic status. Epilepsia 56(Suppl. 1):3–263 (p1067) Sueiras MS, Santamarina E, Lidon RM, Guzman L, Baneras J, Gonzalez M, Toledo M, Salas-Puig X (2015) Use of perampanel (per) in two cases of super-refractory hypoxic myoclonic status. Epilepsia 56(Suppl. 1):3–263 (p1067)
39.
40.
Zurück zum Zitat Strzelczyk A, Klein KM, Willems LM, Rosenow F, Bauer S (2016) Brivaracetam in the treatment of focal and idiopathic generalized epilepsies and of status epilepticus. Expert Rev Clin Pharmacol 9(5):637–645CrossRef Strzelczyk A, Klein KM, Willems LM, Rosenow F, Bauer S (2016) Brivaracetam in the treatment of focal and idiopathic generalized epilepsies and of status epilepticus. Expert Rev Clin Pharmacol 9(5):637–645CrossRef
41.
Zurück zum Zitat Zahnert F, Krause K, Immisch I, Habermehl L, Gorny I, Chmielewska I et al (2018) Brivaracetam in the treatment of patients with epilepsy-first clinical experiences. Front Neurol 9:38CrossRef Zahnert F, Krause K, Immisch I, Habermehl L, Gorny I, Chmielewska I et al (2018) Brivaracetam in the treatment of patients with epilepsy-first clinical experiences. Front Neurol 9:38CrossRef
42.
Zurück zum Zitat Steinig I, von Podewils F, Moddel G, Bauer S, Klein KM, Paule E et al (2017) Postmarketing experience with brivaracetam in the treatment of epilepsies: a multicenter cohort study from Germany. Epilepsia 58(7):1208–1216CrossRef Steinig I, von Podewils F, Moddel G, Bauer S, Klein KM, Paule E et al (2017) Postmarketing experience with brivaracetam in the treatment of epilepsies: a multicenter cohort study from Germany. Epilepsia 58(7):1208–1216CrossRef
43.
Zurück zum Zitat Steinhoff BJ, Bacher M, Bucurenciu I, Hillenbrand B, Intravooth T, Kornmeier R et al (2017) Real-life experience with brivaracetam in 101 patients with difficult-to-treat epilepsy – a monocenter survey. Seizure 48:11–14CrossRef Steinhoff BJ, Bacher M, Bucurenciu I, Hillenbrand B, Intravooth T, Kornmeier R et al (2017) Real-life experience with brivaracetam in 101 patients with difficult-to-treat epilepsy – a monocenter survey. Seizure 48:11–14CrossRef
44.
Zurück zum Zitat Nicolas JM, Hannestad J, Holden D, Kervyn S, Nabulsi N, Tytgat D et al (2016) Brivaracetam, a selective high-affinity synaptic vesicle protein 2A (SV2A) ligand with preclinical evidence of high brain permeability and fast onset of action. Epilepsia 57(2):201–209CrossRef Nicolas JM, Hannestad J, Holden D, Kervyn S, Nabulsi N, Tytgat D et al (2016) Brivaracetam, a selective high-affinity synaptic vesicle protein 2A (SV2A) ligand with preclinical evidence of high brain permeability and fast onset of action. Epilepsia 57(2):201–209CrossRef
45.
Zurück zum Zitat Sargentini-Maier ML, Espie P, Coquette A, Stockis A (2008) Pharmacokinetics and metabolism of 14C-brivaracetam, a novel SV2A ligand, in healthy subjects. Drug Metab Dispos 36(1):36–45CrossRef Sargentini-Maier ML, Espie P, Coquette A, Stockis A (2008) Pharmacokinetics and metabolism of 14C-brivaracetam, a novel SV2A ligand, in healthy subjects. Drug Metab Dispos 36(1):36–45CrossRef
46.
Zurück zum Zitat Stockis A, Sargentini-Maier ML, Horsmans Y (2013) Brivaracetam disposition in mild to severe hepatic impairment. J Clin Pharmacol 53(6):633–641CrossRef Stockis A, Sargentini-Maier ML, Horsmans Y (2013) Brivaracetam disposition in mild to severe hepatic impairment. J Clin Pharmacol 53(6):633–641CrossRef
47.
Zurück zum Zitat Bialer M, Johannessen SI, Levy RH, Perucca E, Tomson T, White HS (2010) Progress report on new antiepileptic drugs: a summary of the Tenth Eilat Conference (EILAT X). Epilepsy Res 92(2–3):89–124CrossRef Bialer M, Johannessen SI, Levy RH, Perucca E, Tomson T, White HS (2010) Progress report on new antiepileptic drugs: a summary of the Tenth Eilat Conference (EILAT X). Epilepsy Res 92(2–3):89–124CrossRef
48.
Zurück zum Zitat Rolan P, Sargentini-Maier ML, Pigeolet E, Stockis A (2008) The pharmacokinetics, CNS pharmacodynamics and adverse event profile of brivaracetam after multiple increasing oral doses in healthy men. Br J Clin Pharmacol 66(1):71–75CrossRef Rolan P, Sargentini-Maier ML, Pigeolet E, Stockis A (2008) The pharmacokinetics, CNS pharmacodynamics and adverse event profile of brivaracetam after multiple increasing oral doses in healthy men. Br J Clin Pharmacol 66(1):71–75CrossRef
49.
Zurück zum Zitat Mumoli L, Palleria C, Gasparini S, Citraro R, Labate A, Ferlazzo E et al (2015) Brivaracetam: review of its pharmacology and potential use as adjunctive therapy in patients with partial onset seizures. Drug Des Devel Ther 9:5719–5725PubMedPubMedCentral Mumoli L, Palleria C, Gasparini S, Citraro R, Labate A, Ferlazzo E et al (2015) Brivaracetam: review of its pharmacology and potential use as adjunctive therapy in patients with partial onset seizures. Drug Des Devel Ther 9:5719–5725PubMedPubMedCentral
50.
Zurück zum Zitat Sargentini-Maier ML, Sokalski A, Boulanger P, Jacobs T, Stockis A (2012) Brivaracetam disposition in renal impairment. J Clin Pharmacol 52(12):1927–1933CrossRef Sargentini-Maier ML, Sokalski A, Boulanger P, Jacobs T, Stockis A (2012) Brivaracetam disposition in renal impairment. J Clin Pharmacol 52(12):1927–1933CrossRef
51.
Zurück zum Zitat Stockis A, Chanteux H, Rosa M, Rolan P (2015) Brivaracetam and carbamazepine interaction in healthy subjects and in vitro. Epilepsy Res 113:19–27CrossRef Stockis A, Chanteux H, Rosa M, Rolan P (2015) Brivaracetam and carbamazepine interaction in healthy subjects and in vitro. Epilepsy Res 113:19–27CrossRef
52.
Zurück zum Zitat von Rosenstiel P (2007) Brivaracetam (UCB 34714). Neurotherapeutics 4(1):84–87CrossRef von Rosenstiel P (2007) Brivaracetam (UCB 34714). Neurotherapeutics 4(1):84–87CrossRef
53.
Zurück zum Zitat Stockis A, Watanabe S, Scheen AJ (2015) Effect of brivaracetam on CYP3A activity, measured by oral midazolam. J Clin Pharmacol 55(5):543–548CrossRef Stockis A, Watanabe S, Scheen AJ (2015) Effect of brivaracetam on CYP3A activity, measured by oral midazolam. J Clin Pharmacol 55(5):543–548CrossRef
54.
Zurück zum Zitat Strzelczyk A, Steinig I, Willems LM, Reif PS, Senft C, Voss M et al (2017) Treatment of refractory and super-refractory status epilepticus with brivaracetam: a cohort study from two German university hospitals. Epilepsy Behav 70(Pt A):177–181CrossRef Strzelczyk A, Steinig I, Willems LM, Reif PS, Senft C, Voss M et al (2017) Treatment of refractory and super-refractory status epilepticus with brivaracetam: a cohort study from two German university hospitals. Epilepsy Behav 70(Pt A):177–181CrossRef
56.
Zurück zum Zitat Strzelczyk A, Kay L, Bauer S, Immisch I, Klein KM, Knake S et al (2018) Use of brivaracetam in genetic generalized epilepsies and for acute, intravenous treatment of absence status epilepticus. Epilepsia 59(8):1549–1556CrossRef Strzelczyk A, Kay L, Bauer S, Immisch I, Klein KM, Knake S et al (2018) Use of brivaracetam in genetic generalized epilepsies and for acute, intravenous treatment of absence status epilepticus. Epilepsia 59(8):1549–1556CrossRef
57.
Zurück zum Zitat Kay L, Reif PS, Belke M, Bauer S, Frund D, Knake S et al (2015) Intranasal midazolam during presurgical epilepsy monitoring is well tolerated, delays seizure recurrence, and protects from generalized tonic-clonic seizures. Epilepsia 56(9):1408–1414CrossRef Kay L, Reif PS, Belke M, Bauer S, Frund D, Knake S et al (2015) Intranasal midazolam during presurgical epilepsy monitoring is well tolerated, delays seizure recurrence, and protects from generalized tonic-clonic seizures. Epilepsia 56(9):1408–1414CrossRef
Metadaten
Titel
Topiramat, Perampanel und Brivaracetam im Status epilepticus
Wie anzuwenden und was können wir erwarten?
verfasst von
Alexandra Rohracher
PD Dr. Christoph Kellinghaus
Adam Strzelczyk
Publikationsdatum
30.08.2018
Verlag
Springer Medizin
Erschienen in
Clinical Epileptology / Ausgabe 4/2018
Print ISSN: 2948-104X
Elektronische ISSN: 2948-1058
DOI
https://doi.org/10.1007/s10309-018-0206-x

Weitere Artikel der Ausgabe 4/2018

Zeitschrift für Epileptologie 4/2018 Zur Ausgabe

Mitteilungen der Arbeitsgemeinschaft für prächirurgische Diagnostik und operative Epilepsietherapie e. V.

Mitteilungen der Arbeitsgemeinschaft für prächirurgische Diagnostik und operative Epilepsietherapie

Mitteilungen der Stiftung Michael

Mitteilungen der Stiftung Michael

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Neu im Fachgebiet Neurologie

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.